Atin Tomar is President & CEO of CPL Biologicals Pvt. Ltd., a joint venture company formed between Cadila Pharmaceuticals Limited, India and Novavax Inc, USA in 2009. CPL Biologicals focuses on research & development, manufacturing and commercialization of Vaccines, Biologics and Diagnostics for human health.
Atin brings with him comprehensive experience in Biotechnology industry in the areas of Vaccines and Biologics, globally. Atin’s expertise spans from Process Development, Scale-up, Technology Transfer and Manufacturing Operations to Business Development, Licensing and Commercialization.
Prior to joining CPL Biologicals, Atin was associated with the Biotechnology industry in various roles. He was involved in the development of Biologics/Bio-therapeutics from the early stages of development to commercial manufacturing at Human Genome Sciences Inc., Amgen Inc. and Syngene International Limited (A Biocon Company). At Dr. Reddy’s Laboratories Ltd., MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. and International Vaccine Institute (IVI) Atin was involved in Business Development & Licensing, Partnerships and Collaborations, Program Management, Alliance Management and Commercialization for Biosimilars and Vaccines.
Atin completed his B.Tech (Hons) in Biotechnology and Biochemical Engineering from the Indian Institute of Technology (IIT) Kharagpur, India, MS in Biological Engineering from the University of Georgia, Athens, USA and Post-Graduate Programme in Management (MBA) in Finance and Strategy & Leadership from the Indian School of Business (ISB), Hyderabad, India.